Analyst Ratings For Acer Therapeutics (NASDAQ:ACER)
Today, William Blair initiated coverage on Acer Therapeutics (NASDAQ:ACER) with a Outperform.
Some recent analyst ratings include
- 2/16/2018-William Blair initiated coverage with a Outperform rating.
- 10/28/2016-Maxim Group was Downgraded by analysts at Maxim Group from a “Buy ” rating to a ” Hold” rating.
- 10/28/2016-Chardan Capital was Downgraded by analysts at Chardan Capital from a “Buy ” rating to a ” Neutral” rating.
- 10/28/2016-Aegis was Downgraded by analysts at Aegis from a “Buy ” rating to a ” Hold” rating.
Recent Insider Trading Activity For Acer Therapeutics (NASDAQ:ACER)
Acer Therapeutics (NASDAQ:ACER) has insider ownership of 6.88% and institutional ownership of 0.07%.
- On 12/14/2017 Steve Aselage, Director, bought 2,000 with an average share price of $12.00 per share and the total transaction amounting to $24,000.00.
- On 11/18/2016 Timothy C Barabe, Director, sold 14,914 with an average share price of $0.55 per share and the total transaction amounting to $8,202.70.
- On 9/17/2014 Timothy C Barabe, Director, bought 10,000 with an average share price of $1.15 per share and the total transaction amounting to $11,500.00.
- On 9/16/2014 Neil K Warma, CEO, bought 10,000 with an average share price of $1.11 per share and the total transaction amounting to $11,100.00.
- On 12/18/2013 Karthik Radhakrishnan, CFO, bought 8,000 with an average share price of $1.70 per share and the total transaction amounting to $13,600.00.
- On 12/18/2013 Scott B Seaman, Director, bought 30,000 with an average share price of $1.70 per share and the total transaction amounting to $51,000.00.
- On 8/8/2013 Karthik Radhakrishnan, CFO, bought 50,000 with an average share price of $1.50 per share and the total transaction amounting to $75,000.00.
Recent Trading Activity for Acer Therapeutics (NASDAQ:ACER)
Shares of Acer Therapeutics closed the previous trading session at 18.13 up +1.22 7.21% with 17.989999771118164 shares trading hands.